Innovating Works

PEPTOMYC

Activa
MYCureX: FIRST-IN-CLASS MYC INHIBITOR: THE MAKING OF A BREAKTHROUGH CANCER THERAPY PEPTOMYC tramitó un HORIZON EUROPE: HORIZON-EIC-2023-ACCELERATOR-01 Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with very few and often ineffective therapeutic options. Despite...
2024-02-08 - 2025-12-31 | Financiado
MYCure: Innovative cancer therapy through Myc inhibition taking OMO 103 to market PEPTOMYC tramitó un H2020: H2020-EIC-SMEInst-2018-2020 Cancer is a global challenge with 9 millions (M) deaths annually and new cases projected to rise by 70% in the 20 years, and there is a clea...
2019-08-28 - 2022-12-31 | Financiado
PEPTO1: Feasibility study of a novel treatment for cancer based on a recombinant peptide therapy PEPTOMYC tramitó un H2020: H2020-SMEInst-2014-2015 Peptomyc S.L. is an SME created to develop a new, first-in-class, cancer therapy using innovative anti-Myc peptides. Myc is an oncogene dere...
2016-02-16 - 2016-07-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.